Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Alcon Inc. and RxSight, Inc.: Initiation of Research Coverage

    Analyst Steven Lichtman initiated research coverage of Alcon Inc. (ALC $80.42) and RxSight, Inc. (RXST $9.11) and resumed William Blair’s coverage of The Cooper Companies, Inc. (COO $80.48) and Sight Sciences, Inc. (SGHT $6.03). All four companies are in the medical technology industry and specialize in vision and eye care products.

    Read more

  • Carlisle Companies Incorporated: Initiation of Research Coverage

    William Blair initiated research coverage of Carlisle Companies Incorporated (CSL $341.01), the leading manufacturer of single-ply commercial roofing membranes and a variety of building envelope solutions.

    Read more

  • Economics Weekly: The Capital Investment Wave Continues

    In this Economics Weekly, we outline our key arguments for the capex revival and what has changed over the last year or so, particularly with regard to the policies that the Trump administration is attempting to institute.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures